Article

You have full text access to this OnlineOpen article

Germline humanization of a murine Aβ antibody and crystal structure of the humanized recombinant Fab fragment

  1. Remy Robert*,
  2. Victor A. Streltsov,
  3. Janet Newman,
  4. Lesley A. Pearce,
  5. Kim L. Wark†,
  6. Olan Dolezal†

Article first published online: 15 DEC 2009

DOI: 10.1002/pro.312

Issue

Protein Science

Protein Science

Volume 19, Issue 2, pages 299–308, February 2010

Additional Information

How to Cite

Robert, R., Streltsov, V. A., Newman, J., Pearce, L. A., Wark, K. L. and Dolezal, O. (2010), Germline humanization of a murine Aβ antibody and crystal structure of the humanized recombinant Fab fragment. Protein Science, 19: 299–308. doi: 10.1002/pro.312

Author Information

  1. CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia

  1. †

    Kim L. Wark and Olan Dolezal contributed equally to this work.

*CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia

Publication History

  1. Issue published online: 21 JAN 2010
  2. Article first published online: 15 DEC 2009
  3. Accepted manuscript online: 15 DEC 2009 12:00AM EST
  4. Manuscript Accepted: 30 NOV 2009
  5. Manuscript Revised: 26 NOV 2009
  6. Manuscript Received: 23 OCT 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (877K)

References

  • 1
    Masters CL, Beyreuther K ( 2006) Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain 129: 2823–2839.
  • 2
    Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B ( 1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733–736.
  • 3
    Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG ( 2009) Aβ aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med 13: 412–421.
    Direct Link:
  • 4
    Lorenzo A, Yankner BA ( 1994) β-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91: 12243–12247.
  • 5
    Tsai J, Grutzendler J, Duff K, Gan WB ( 2004) Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 11: 1181–1183.
  • 6
    Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein, WL ( 1998) Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448–6453.
  • 7
    Wilcock DM, Colton CA ( 2008) Anti-amyloid-β immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15: 555–569.
  • 8
    Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P ( 1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173–177.
  • 9
    Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C ( 2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61: 46–54.
  • 10
    Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T ( 2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916–919.
  • 11
    Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE ( 2006) Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116: 193–201.
  • 12
    Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB ( 2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J Neurosci 25: 629–636.
  • 13
    Tamura Y, Hamajima K, Matsui K, Yanoma S, Narita M, Tajima N, Xin KQ, Klinman D, Okuda K ( 2005) The F(ab)'2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain. Neurobiol Dis 20: 541–549.
  • 14
    Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D ( 2006) Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci 26: 5340–5346.
  • 15
    Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K ( 1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271: 22908–22914.
  • 16
    Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, Hudson PJ, Wark KL ( 2009) Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel 22: 199–208.
  • 17
    Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC, Jr ( 1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45: 879–885.
  • 18
    Hwang WY, Almagro JC, Buss TN, Tan P, Foote J ( 2005) Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods 36: 35–42.
  • 19
    Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc MP, Thullier P ( 2008) Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 384: 1400–1407.
  • 20
    Foote J, Winter G ( 1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224: 487–499.
  • 21
    Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kondo H, Umetsu M, Sone Y, Asano R, Kumagai I ( 2008) Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem 283: 1156–1166.
  • 22
    Ye Y, Godzik A ( 2003) Flexible structure alignment by chaining aligned fragment pairs allowing twists. Bioinformatics 19 ( Suppl 2): ii246–ii255.
  • 23
    Miles LA, Wun KS, Crespi GAN, Fodero-Tavoletti MT, Galatis D, Bagley CJ, Beyreuther K, Masters CL, Cappai R, McKinstry WJ, Barnham KJ, Parker MW ( 2008) Amyloid-β–Anti-Amyloid-β complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol 377: 181–192.
  • 24
    Stanfield RL, Zemla A, Wilson IA, Rupp B ( 2006) Antibody elbow angles are influenced by their light chain class. J Mol Biol 357: 1566–1574.
  • 25
    Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM ( 2008) Rapid microglial response around amyloid pathology after systemic anti-Aβ antibody administration in PDAPP mice. J Neurosci 28: 14156–14164.
  • 26
    Cardinale A, Biocca S ( 2008) The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol Med 14: 373–380.
  • 27
    Giudicelli V, Chaume D, Lefranc MP ( 2004) IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 32: W435–W440.
  • 28
    Yousfi Monod M, Giudicelli V, Chaume D, Lefranc MP ( 2004) IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics 20( Suppl 1): i379–i385.
  • 29
    Otwinowski Z, Minor W ( 1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307–326.
  • 30
    McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ ( 2007) Phaser crystallographic software. J Appl Crystallogr 40: 658–674.
    Direct Link:
  • 31
    Collaborative Computational Project Number 4 ( 1994) The CCP4 suite: programs for protein crystallography. Acta Cryst D 50: 760–763.
    Direct Link:
  • 32
    Murshudov GN, Vagin AA, Dodson EJ ( 1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst D 53: 240–255.
    Direct Link:
  • 33
    McRee DE ( 1999) XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J Struct Biol 125: 156–165.
  • 34
    Brünger AT ( 1992) The Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355: 472–474.
  • 35
    Winn MD, Isupov MN, Murshudov GN ( 2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Cryst D 57: 122–133.
    Direct Link:
  • 36
    Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, Myszka DG ( 2006) Exploring “one-shot” kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 358: 281–288.
  • 37
    LeVine H, III ( 1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2: 404–410.
View Full Article (HTML) Get PDF (877K)